Sigilon Therapeutics, Inc.

NasdaqGS:SGTX Stock Report

Market Cap: US$56.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Sigilon Therapeutics Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Rogerio Coelho

Chief executive officer

US$2.0m

Total compensation

CEO salary percentage29.70%
CEO tenure5.6yrs
CEO ownershipn/a
Management average tenure2.3yrs
Board average tenure5.7yrs

Recent management updates

Recent updates

Analysis Article • Apr 17

Benign Growth For Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Underpins Stock's 34% Plummet

The Sigilon Therapeutics, Inc. ( NASDAQ:SGTX ) share price has softened a substantial 34% over the previous 30 days...
Seeking Alpha • Aug 04

Sigilon Therapeutics GAAP EPS of -$0.44, revenue of $2.88M

Sigilon Therapeutics press release (NASDAQ:SGTX): Q2 GAAP EPS of -$0.44. Collaboration Revenue of $2.88M (+6.7% Y/Y). Cash, cash equivalents and marketable securities were $88.2 million as of June 30, 2022 compared to $123.4 million as of December 31, 2021.
Analysis Article • Mar 04

What Percentage Of Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Shares Do Insiders Own?

A look at the shareholders of Sigilon Therapeutics, Inc. ( NASDAQ:SGTX ) can tell us which group is most powerful...

CEO Compensation Analysis

How has Rogerio Coelho's remuneration changed compared to Sigilon Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

-US$30m

Mar 31 2023n/an/a

-US$37m

Dec 31 2022US$2mUS$601k

-US$44m

Sep 30 2022n/an/a

-US$55m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$72m

Dec 31 2021US$6mUS$578k

-US$77m

Sep 30 2021n/an/a

-US$75m

Jun 30 2021n/an/a

-US$68m

Mar 31 2021n/an/a

-US$61m

Dec 31 2020US$810kUS$528k

-US$55m

Sep 30 2020n/an/a

-US$52m

Jun 30 2020n/an/a

-US$51m

Mar 31 2020n/an/a

-US$47m

Dec 31 2019US$723kUS$508k

-US$44m

Compensation vs Market: Rogerio's total compensation ($USD2.02M) is above average for companies of similar size in the US market ($USD754.53K).

Compensation vs Earnings: Rogerio's compensation has been consistent with company performance over the past year.

CEO

Rogerio Coelho (59 yo)

5.6yrs
Tenure
US$2,024,671
Compensation

Dr. Rogerio Vivaldi Coelho, M.D., M.B.A., is Independent Director of Crinetics Pharmaceuticals, Inc. from January 03, 2022. He was Chief Global Therapeutic Operations Officer and Executive Vice President o...

Leadership Team

NamePositionTenureCompensationOwnership
Rogerio Coelho
President5.6yrsUS$2.02mno data
Philip Ashton-Rickardt
Chief Scientific Officer2.2yrsUS$902.19k0%
$ 0
Robert Langer
Co-Founder & Member of Scientific Advisory Boardno dataUS$101.90kno data
Daniel Anderson
Co-Founder & Member of Scientific Advisory Boardno dataUS$46.92kno data
Omid Veiseh
Co-Founderno datano datano data
José Oberholzer
Co-Founderno datano datano data
Arturo Vegas
Co-Founderno datano datano data
Josias Fantato Pontes
CFO, Principal Accounting Officer & Treasurer1.5yrsno data0%
$ 0
Bernd Kullmann
Senior VP and Head of Operations & Project Managementless than a yearno datano data
Matthew Kowalsky
Chief of Staff3.6yrsno data0%
$ 0
Robert Windsor
VP & Head of Investor Relations2.3yrsno datano data
Olivia Kelly
Senior VP & Head of Diabetes Research5.6yrsno datano data
2.3yrs
Average Tenure
57.5yo
Average Age

Experienced Management: SGTX's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Rogerio Coelho
President5.6yrsUS$2.02mno data
Robert Langer
Co-Founder & Member of Scientific Advisory Boardno dataUS$101.90kno data
Daniel Anderson
Co-Founder & Member of Scientific Advisory Boardno dataUS$46.92kno data
Michael Rosenblatt
Member of Scientific Advisory Board3.6yrsno datano data
Ulrik Nielsen
Member of Scientific Advisory Board3.6yrsno datano data
Stephen Newman Oesterle
Independent Director7.6yrsUS$51.24k0%
$ 0
Robert R. Ruffolo
Independent Director7.6yrsUS$44.74k0%
$ 0
Douglas Cole
Independent Chairman of The Board8.6yrsUS$87.74k0%
$ 0
John Cox
Independent Director4.3yrsUS$44.74k0%
$ 0
Constance Cepko
Member of Scientific Advisory Board5.8yrsno datano data
Eric Shaff
Independent Director5.8yrsUS$54.74k0%
$ 0
Kavita Patel
Independent Director3.2yrsUS$45.80k0%
$ 0
5.7yrs
Average Tenure
60yo
Average Age

Experienced Board: SGTX's board of directors are considered experienced (5.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/08/15 10:39
End of Day Share Price 2023/08/10 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sigilon Therapeutics, Inc. is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Thomas ShraderBTIG
Whitney IjemCanaccord Genuity